Compare CPSH & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPSH | FLNA |
|---|---|---|
| Founded | 1984 | 1998 |
| Country | United States | United States |
| Employees | N/A | 20 |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.9M | 61.8M |
| IPO Year | 1995 | N/A |
| Metric | CPSH | FLNA |
|---|---|---|
| Price | $5.92 | $1.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 486.5K | 382.6K |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 113.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.41 | N/A |
| Revenue Next Year | $20.16 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.11 | $1.16 |
| 52 Week High | $6.85 | $2.03 |
| Indicator | CPSH | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 63.11 | 41.11 |
| Support Level | $3.20 | $1.16 |
| Resistance Level | $6.85 | $1.80 |
| Average True Range (ATR) | 0.63 | 0.08 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 79.08 | 48.39 |
CPS Technologies Corp designs, manufactures, and sells high-performance material solutions for customers across various markets, including transportation, energy, automotive, electronics, telecommunications, aerospace, and defense. The company develops and applies proprietary expertise in metal matrix composites (MMCs), which are engineered materials combining metals and ceramics to achieve enhanced performance properties. It also provides baseplates and housings used in radar, satellite and avionics applications. The company provides lids and heat spreaders used with integrated circuits in Internet switches and routers. The majority of the company's revenue is derived from the sale of its products in the United States of America.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.